Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

The approval was based on results from the phase 3 POLO trial of Lynparza (olaparib) in advanced pancreatic cancer patients whose tumours carry BRCA mutations. ... In the POLO trial, Lynparza nearly doubled median progression-free survival versus placebo

Latest news

  • BMS’ Opdivo combo misses the mark in pancreatic cancer BMS’ Opdivo combo misses the mark in pancreatic cancer

    The patient population included 160 people with locally advanced or metastatic pancreatic cancer that had progressed during or after one line of chemotherapy. ... It also carries poor survival rates – less than 7% of patients are still alive five years

  • AZ revenues rise, but it says coronavirus could hit 2020 AZ revenues rise, but it says coronavirus could hit 2020

    Product sales were up 12% to $23.57bn for the full-year, driven by cancer products and turnover in emerging markets, although there was a bit of a slowdown to 8% ... Imfinzi meanwhile grew 62% to $424m, helped by increased use as maintenance therapy for

  • Eisai agrees to pull obesity drug Belviq after safety alert Eisai agrees to pull obesity drug Belviq after safety alert

    Weight-loss drug linked to increased risk of cancer. Eisai has moved swiftly to comply with an FDA request to pull its obesity drug Belviq off the market after it was ... In 2010, the FDA rejected the first marketing application for the drug, filed by

  • Revenue growth at Ipsen numbs pain of palovarotene calamity Revenue growth at Ipsen numbs pain of palovarotene calamity

    The French speciality drugmaker posted 2.58bn in sales for the full-year, up nearly 15%, thanks to another strong performance for cancer drugs Somatuline (lanreotide) and Cabometyx (cabozantinib) as well ... It also has data due in the coming months for

  • NantKwest rockets on promising pancreatic cancer data NantKwest rockets on promising pancreatic cancer data

    One patient demonstrated a complete response following treatment. California-based biotech NantKwest (NK) has revealed promising results from one of the first pancreatic cancer patients dosed with its experimental cancer therapy, ... Pancreatic cancer is

More from news
Approximately 29 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.

Communiqué Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Quick links

Infographics

Multimedia